According to the Securities Times APP, on Wednesday, Hims & Hers Health (HIMS.US) rose by over 5%, hitting a new historical high at $32.23. On the news front, institutions like Hunterbrook Media, which follows short sellers like Citron Research, released a report on Monday pointing out that U.S. President Trump has nominated Marty Makary to be the head of the Food and Drug Administration (FDA). This nomination could greatly benefit Hims & Hers because Makary is an executive at Sesame Inc., while both Sesame and Hims & Hers are startup companies selling composite GLP-1 weight loss pharmaceuticals.

The hedge fund Hunterbrook Capital under Hunterbrook stated that they are now bullish on Hims & Hers' stocks, in contrast to their short position in June, when they were focused on the sale of GLP-1 injectables online by the company.